Randomized Comparison of Piperacillin–Tazobactam Plus Amikacin Versus Cefoperazone-Sulbactam Plus Amikacin for Management of Febrile Neutropenia in Children with Lymphoma and Solid Tumors
Authors:
- 9 January 2013
- journal article
- research article
- Published by Taylor & Francis in Pediatric Hematology and Oncology
- Vol. 30 (2) , 141-148
Abstract
The objective of this study was to compare the effectiveness of piperacillin–tazobactam (PIP/TAZO) plus amikacin (AMK) (PIP/TAZO+AMK) versus cefoperazone–sulbactam (CS) plus AMK (CS+AMK) for the treatment of febrile neutropenia (FN) in children with cancer. The study was designed prospectively and randomized in 0- to 18-year-old children with lymphoma or solid tumor who were hospitalized with FN diagnosis. Consecutively randomized patients received either PIP/TAZO 360 mg/kg/day in 4 doses plus AMK 15 mg/kg/day in 3 doses or CS 100 mg/kg/day in 3 doses plus AMK 15 mg/kg/day in 3 doses intravenously. Treatment modification was defined as any change in the initial empirical antibiotic therapy. A total of 116 FN episodes were managed in 46 patients (26 boys and 20 girls) with a median age of 6.5 years (range .8–17.0) during the study period. Success rates without modification of therapy were 47.5% and 52.6% in PIP/TAZO+AMK group and CS+AMK group, respectively (P >.05). No statistical difference was found between treatment groups in terms of durations of neutropenia, fever, and hospitalization. The overall success rate in all groups was 97.4%. No major side effect was observed in either group during the course of the study. Our study is the first to compare the effectiveness of PIP/TAZO+AMK and CS+AMK therapies. Both combinations were effective and safe as empirical therapy for febrile neutropenic patients.Keywords
This publication has 20 references indexed in Scilit:
- A Meta-analysis of Antipseudomonal Penicillins and Cephalosporins in Pediatric Patients With Fever and NeutropeniaThe Pediatric Infectious Disease Journal, 2012
- Piperacillin/tazobactam versus cefozopran for the empirical treatment of pediatric cancer patients with febrile neutropeniaPediatric Blood & Cancer, 2011
- Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2011
- Imipenem–cilastatin versus piperacillin–tazobactam as monotherapy in febrile neutropeniaPediatrics International, 2010
- Admission Clinical and Laboratory Factors Associated With Death in Children With Cancer During a Febrile Neutropenic EpisodeThe Pediatric Infectious Disease Journal, 2007
- A prospective, multicentric scoring system to predict mortality in febrile neutropenic children with cancerCancer, 2007
- MONOTHERAPY WITH PIPERACILLIN/TAZOBACTAM VERSUS CEFEPIME AS EMPIRICAL THERAPY FOR FEBRILE NEUTROPENIA IN PEDIATRIC CANCER PATIENTS: A Randomized ComparisonPediatric Hematology and Oncology, 2006
- Piperacillin-tazobactam and netilmicin as a safe and efficacious empirical treatment of febrile neutropenic childrenSupportive Care in Cancer, 2004
- Meropenem Plus Amikacin Versus Piperacillin-Tazobactam Plus Netilmicin as Empiric Therapy for High-Risk Febrile Neutropenia in ChildrenPediatric Hematology and Oncology, 2004
- Imipenem or cefoperazone-sulbactam combined with vancomycin for therapy of presumed or proven infection in neutropenic cancer patientsEuropean Journal of Clinical Microbiology & Infectious Diseases, 1996